Lambda has developed organoid model for inflammatory diseases. We offer inflammation organoid model associated with Inflammatory Bowel Disease-Leaky Gut modeling.
Inflammatory Bowel Disease (IBD) refers to a chronic condition characterized by inflammation within the gastrointestinal tract, causing inflammation of the intestinal walls. In Lambda, we provide a solution for evaluating the efficacy of probiotics and drugs in restoring barrier function using a leaky gut model that involves treating inflammatory stimuli to weaken the intestinal barrier caused by inflammatory reactions.
Inflammatory Bowel Disease (IBD) refers to a chronic condition characterized by inflammation within the gastrointestinal tract, causing inflammation of the intestinal walls. In Lambda, we provide a solution for evaluating the efficacy of probiotics and drugs in restoring barrier function using a leaky gut model that involves treating inflammatory stimuli to weaken the intestinal barrier caused by inflammatory reactions.
Leaky gut model
Leaky gut syndrome is an intestinal disease in which bacteria and toxins enter the bloodstream due to a weakened intestinal barrier. It is mainly caused by an inflammatory response and can be caused by food, intestinal microbial imbalance, and lifestyle habits.
Assay process
Technical
Leaky gut modeling immunostaining
Verification that with increasing doses of LPS-dependent treatment, the expression of ZO-1, a tight junction marker, decreased.
Dextran-FITC permeability assay
The restoration of intestinal lining function by the drug was confirmed by observing that dextran did not penetrate into the cells after treatment with the drug.
Immunofluorescence
In the group treated with Lactobacillus, the expression of ZO-1 was comparable to the control group, in contrast to the only LPS treatment group. This confirms the restoration of intestinal function by LPS.